1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Introduction
2.2. Define: Research Objective
2.3. Determine: Research Design
2.4. Prepare: Research Instrument
2.5. Collect: Data Source
2.6. Analyze: Data Interpretation
2.7. Formulate: Data Verification
2.8. Publish: Research Report
2.9. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidences of ovarian cancer around the globe
5.1.1.2. Increasing geriatric population of women around the world
5.1.1.3. Adoption of novel drugs and strong developmental pipeline
5.1.2. Restraints
5.1.2.1. Adverse impact of cancer drugs on the human body
5.1.3. Opportunities
5.1.3.1. Rising funding in the healthcare industry by the government in developing countries
5.1.3.2. Developments in ovarian cancer drugs in emerging economies
5.1.4. Challenges
5.1.4.1. Cost associated with the treatment of ovarian cancer is high
5.2. Cumulative Impact of COVID-19

6. Ovarian Cancer Drugs Market, by Therapeutics Class
6.1. Introduction
6.2. Angiogenesis Inhibitors
6.3. PARP Inhibitors
6.4. PD-L1 Inhibitors

7. Ovarian Cancer Drugs Market, by Modality
7.1. Introduction
7.2. Chemotherapy
7.3. Hormonal Therapy
7.4. Targeted Therapy

8. Ovarian Cancer Drugs Market, by Drugs
8.1. Introduction
8.2. Avastin
8.3. Carboplatin
8.4. Doxil
8.5. Lynparza
8.6. Yondelis

9. Americas Ovarian Cancer Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Ovarian Cancer Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand

11. Europe, Middle East & Africa Ovarian Cancer Drugs Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Allergan plc
13.2. AstraZeneca Plc
13.3. Boehringer Ingelheim
13.4. Clovis Oncology
13.5. F. Hoffmann-La Roche AG
13.6. Johnson & Johnson
13.7. Merck & Co., Inc.
13.8. Pfizer, Incn
13.9. Syndax Pharmaceuticals, Inc.
13.10. Tesaro
13.11. Zeltia Group

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. GLOBAL OVARIAN CANCER DRUGS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL OVARIAN CANCER DRUGS MARKET: MARKET DYNAMICS
FIGURE 3. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2020 VS 2027 (%)
FIGURE 4. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2020 VS 2027 (USD MILLION)
FIGURE 5. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2027
FIGURE 6. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, 2018-2027 (USD MILLION)
FIGURE 7. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 8. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, 2018-2027 (USD MILLION)
FIGURE 9. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 10. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2027 (USD MILLION)
FIGURE 11. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 12. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2020 VS 2027 (%)
FIGURE 13. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2020 VS 2027 (USD MILLION)
FIGURE 14. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2027
FIGURE 15. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2027 (USD MILLION)
FIGURE 16. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 17. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2027 (USD MILLION)
FIGURE 18. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 19. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2027 (USD MILLION)
FIGURE 20. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 21. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2020 VS 2027 (%)
FIGURE 22. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2020 VS 2027 (USD MILLION)
FIGURE 23. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2027
FIGURE 24. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY AVASTIN, 2018-2027 (USD MILLION)
FIGURE 25. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY AVASTIN, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 26. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CARBOPLATIN, 2018-2027 (USD MILLION)
FIGURE 27. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CARBOPLATIN, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 28. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY DOXIL, 2018-2027 (USD MILLION)
FIGURE 29. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY DOXIL, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 30. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY LYNPARZA, 2018-2027 (USD MILLION)
FIGURE 31. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY LYNPARZA, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 32. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY YONDELIS, 2018-2027 (USD MILLION)
FIGURE 33. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY YONDELIS, BY REGION, 2020 VS 2027 (USD MILLION)
FIGURE 34. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 35. ARGENTINA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 36. BRAZIL OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 37. CANADA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 38. MEXICO OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 39. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 40. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 41. AUSTRALIA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 42. CHINA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 43. INDIA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 44. INDONESIA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 45. JAPAN OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 46. MALAYSIA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 47. PHILIPPINES OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 48. SINGAPORE OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 49. SOUTH KOREA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 50. TAIWAN OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 51. THAILAND OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 52. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 53. FRANCE OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 54. GERMANY OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 55. ITALY OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 56. NETHERLANDS OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 57. QATAR OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 58. RUSSIA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 59. SAUDI ARABIA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 60. SOUTH AFRICA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 61. SPAIN OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 62. UNITED ARAB EMIRATES OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 63. UNITED KINGDOM OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
FIGURE 64. GLOBAL OVARIAN CANCER DRUGS MARKET: FPNV POSITIONING MATRIX
FIGURE 65. GLOBAL OVARIAN CANCER DRUGS MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 66. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL OVARIAN CANCER DRUGS MARKET, BY TYPE

List of Tables

TABLE 1. GLOBAL OVARIAN CANCER DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2027 (USD MILLION)
TABLE 4. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2018-2027 (USD MILLION)
TABLE 5. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2027 (USD MILLION)
TABLE 6. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2027 (USD MILLION)
TABLE 7. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2027 (USD MILLION)
TABLE 8. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2027 (USD MILLION)
TABLE 9. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2027 (USD MILLION)
TABLE 10. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2027 (USD MILLION)
TABLE 11. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2027 (USD MILLION)
TABLE 12. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY AVASTIN, BY REGION, 2018-2027 (USD MILLION)
TABLE 13. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY CARBOPLATIN, BY REGION, 2018-2027 (USD MILLION)
TABLE 14. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY DOXIL, BY REGION, 2018-2027 (USD MILLION)
TABLE 15. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY LYNPARZA, BY REGION, 2018-2027 (USD MILLION)
TABLE 16. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY YONDELIS, BY REGION, 2018-2027 (USD MILLION)
TABLE 17. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 18. ARGENTINA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 19. BRAZIL OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 20. CANADA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 21. MEXICO OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 22. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 23. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 24. AUSTRALIA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 25. CHINA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 26. INDIA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 27. INDONESIA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 28. JAPAN OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 29. MALAYSIA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 30. PHILIPPINES OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 31. SINGAPORE OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 32. SOUTH KOREA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 33. TAIWAN OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 34. THAILAND OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 35. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 36. FRANCE OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 37. GERMANY OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 38. ITALY OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 39. NETHERLANDS OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 40. QATAR OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 41. RUSSIA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 42. SAUDI ARABIA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 43. SOUTH AFRICA OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 44. SPAIN OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 45. UNITED ARAB EMIRATES OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 46. UNITED KINGDOM OVARIAN CANCER DRUGS MARKET SIZE, 2018-2027 (USD MILLION)
TABLE 47. GLOBAL OVARIAN CANCER DRUGS MARKET: SCORES
TABLE 48. GLOBAL OVARIAN CANCER DRUGS MARKET: BUSINESS STRATEGY
TABLE 49. GLOBAL OVARIAN CANCER DRUGS MARKET: PRODUCT SATISFACTION
TABLE 50. GLOBAL OVARIAN CANCER DRUGS MARKET: RANKING
TABLE 51. GLOBAL OVARIAN CANCER DRUGS MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 52. GLOBAL OVARIAN CANCER DRUGS MARKET: MERGER & ACQUISITION
TABLE 53. GLOBAL OVARIAN CANCER DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 54. GLOBAL OVARIAN CANCER DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 55. GLOBAL OVARIAN CANCER DRUGS MARKET: INVESTMENT & FUNDING
TABLE 56. GLOBAL OVARIAN CANCER DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 57. GLOBAL OVARIAN CANCER DRUGS MARKET: LICENSE & PRICING

Companies Mentioned

Allergan plc
AstraZeneca Plc
Boehringer Ingelheim
Clovis Oncology
F. Hoffmann-La Roche AG
Johnson & Johnson
Merck & Co., Inc.
Pfizer, Incn
Syndax Pharmaceuticals, Inc.
Tesaro
Zeltia Group